Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
MacroGenics, Inc. develops antibody-based therapeutics for cancer, with pipeline work built around monoclonal antibodies, DART and TRIDENT multi-specific molecules, and antibody-drug conjugates. Company news commonly covers clinical and regulatory updates for lorigerlimab, MGC026 and MGC028, including FDA communications tied to study conduct and safety monitoring.
Updates also address financial results, capital-resource commentary, strategic collaborations and licensing economics, including royalty interests tied to ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte.
Summary not available.
Summary not available.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on antibody-based cancer therapies, announced its management's participation in several upcoming investor conferences. Key events include:
- Stifel 2023 Targeted Oncology Days: Presentation by Scott Koenig on April 26, 2023, at 2:00 pm ET.
- H.C. Wainwright BioConnect Investor Conference: Fireside chat with Scott Koenig on May 2, 2023, at 1:00 pm ET.
- JMP Securities Life Sciences Conference: Fireside chat with Scott Koenig on May 15, 2023, at 9:30 am ET.
Investors can access webcasts of these presentations in the Investor Relations section of MacroGenics' website, with archived replays available for 30 days. The company utilizes advanced antibody technology to develop innovative therapeutics.
MacroGenics, Inc. (NASDAQ: MGNX) announced a $15 million milestone payment from Incyte following FDA approval of ZYNYZ™ (retifanlimab-dlwr), a monoclonal antibody for treating Merkel cell carcinoma. Originally developed by MacroGenics and licensed to Incyte in October 2017, ZYNYZ's approval marks the third product launch from MacroGenics' pipeline. Additionally, MacroGenics stands to gain up to $320 million in remaining development and regulatory milestones, $330 million in commercial milestones, and a 15% to 24% royalty on global net sales. The CEO expressed satisfaction over this development, highlighting its significance for patient treatment options.
MacroGenics, Inc. (MGNX) announced its corporate progress and financial results for 2022, highlighting a cash runway extending through 2025 due to $250 million in non-dilutive funding. Preliminary data on lorigerlimab in metastatic castration-resistant prostate cancer (mCRPC) showed promising results, with 28.6% of patients achieving ≥ 50% PSA reduction. The TAMARACK study was modified to accelerate data readout. Total revenue increased to $151.9 million, up from $77.4 million in 2021, while net loss decreased to $119.8 million. Upcoming developments include a randomized Phase 2 study of lorigerlimab and advancements in ADC candidates.
MacroGenics has expanded its collaboration with Synaffix, adding up to four antibody-drug conjugate (ADC) programs. This agreement, evolving from a deal made in February 2022, includes potential payments of up to $2.2 billion and tiered royalties on net sales. MacroGenics can now pursue up to seven ADC programs, combining its proprietary technologies with Synaffix's advanced linker-payload technologies. This collaboration is positioned to enhance the development of innovative treatments for cancer, significantly leveraging Synaffix's GlycoConnect™, HydraSpace™, and toxSYN™ technologies for better efficacy and tolerability in ADCs.
MacroGenics, Inc. (Nasdaq: MGNX) has announced an agreement to sell its royalty interest on future global net sales of TZIELD to a subsidiary of DRI Healthcare Trust for up to $200 million. MacroGenics will receive a $100 million upfront payment for a single-digit royalty. The company retains other economic interests related to TZIELD, including potential milestone payments. Additionally, MacroGenics can earn an extra $50 million tied to specific advancements in TZIELD's treatment of type 1 diabetes and another $50 million based on net sales achievements.
MacroGenics, Inc. (Nasdaq: MGNX) announced it will release its fourth quarter 2022 financial results on March 15, 2023, after market close. A conference call to discuss these results and corporate progress will follow at 4:30 pm ET on the same day. Investors can register in advance for telephone participation, receiving a confirmation email with access details. A listen-only webcast will also be available on the company's website under the Investor Relations section. MacroGenics is focused on developing innovative monoclonal antibody therapeutics for cancer treatment, leveraging proprietary antibody technology and strategic collaborations.
MacroGenics, Inc. (Nasdaq: MGNX) announced its participation in significant investor conferences in March 2023. The company's President & CEO, Scott Koenig, will join the TD Cowen’s 43rd Annual Health Care Conference in Boston on March 7, 2023, for a corporate panel discussion. Additionally, he will participate in a fireside chat at the Barclays Global Healthcare Conference in Miami on March 14, 2023. Management will also engage in one-on-one meetings during both events. Webcasts of the presentations will be available on the company's Investor Relations website, with an archived replay for 30 days.
MacroGenics announced preliminary results from the Phase 1 trial of lorigerlimab for metastatic castration-resistant prostate cancer (mCRPC). In the cohort expansion, 12 of 42 patients achieved ≥ 50% reduction in PSA levels, while 9 patients (21.4%) had ≥ 90% reduction. The overall safety profile was manageable, with the company preparing to launch a Phase 2 study in mCRPC later in 2023. These findings are set to be presented at the ASCO-GU Symposium, showcasing the therapeutic potential of lorigerlimab and indicating promising efficacy in mCRPC patients.